Our unit combines diagnostic proceedings and multidisciplinary care for ALS patients with clinical research focused on cognitive impairment assessment, quality of life studies, biomarkers and clinical trials. Comprehensive multidisciplinary care is provided by a team of neurologists, psychologists and nurses supported by neumologists, nutritionists and palliative care specialists in hospital or home-based. A rehabilitation team provides motor, respiratory and speech therapies.
More than 15 phase II and III clinical trials have been carried out since 1990 when Dr Mora created the first Spanish ALS unit at Hospital Carlos III and since 2004 till now at Hospital La Paz–Carlos III working as a single Hospital.
Contact
LocationCalle de Sinesio Delgado, 10, 28029 Madrid, Spanje
Specialists
Current trials
Recruiting
Phase iii
ATLAS trial
Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Recruiting
Phase iii
FUSION trial
Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Active
Phase iii
PHOENIX trial
Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Active
Phase iii
ADORE trial
Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Active
Phase iii
TUDCA-ALS
Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.